肿瘤细胞治疗研究
英文原题：Advances in PSMA-targeted therapy for prostate cancer.
前列腺特异性膜抗原（PSMA）是一种位于细胞膜上的跨膜糖蛋白，在前列腺癌（PCa）中特异性高表达。
前列腺特异性膜抗原（PSMA）是一种位于细胞膜上的跨膜糖蛋白，在前列腺癌（PCa）中特异性高表达，其表达水平还与肿瘤侵袭性相关。PSMA 作为 PCa 的分子靶点，过去 20 年来受到广泛研究。目前大量证据表明，PSMA 靶向治疗 PCa 已取得显著进展。本文综述不同类型的 PSMA 靶向治疗，包括放射性配体治疗（¹⁷⁷Lu-PSMA-RLT、²²⁵Ac-PSMA-RLT）、抗体药物偶联物（MLN2704、PSMA-MMAE、MEDI3726）、细胞免疫治疗（CAR-T、CAR/NK-92、PSMA 靶向 BiTE）、光动力治疗、影像引导手术（核素引导、荧光引导及多模态影像引导手术），以及超声介导的纳米气泡破坏。
Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein located on the cell membrane, is specifically and highly expressed in prostate cancer (PCa). Besides, its expression level is related to tumor invasiveness. As a molecular target of PCa, PSMA has been extensively studied in the past two decades. Currently, a great deal of evidence suggests that significant progresses have been made in the PSMA-targeted therapy of PCa. Herein, different PSMA-targeted therapies for PCa are reviewed, including radioligand therapy ( 177 Lu-PSMA-RLT, 225 Ac-PSMA-RLT), antibody-drug conjugates (MLN2704, PSMA-MMAE, MEDI3726), cellular immunotherapy (CAR-T, CAR/NK-92, PSMA-targeted BiTE), photodynamic therapy, imaging-guided surgery (radionuclide-guided surgery, fluorescence-guided surgery, multimodal imaging-guided surgery), and ultrasound-mediated nanobubble destruction.
MEMBER ACCOUNT
登录成功会直接打开下一页。
